Kawasaki disease is a form of acute systemic vasculitis of childhood, which was first described in 1967.1 Since that time over 80 000 cases have occurred in Japan. Although the disease is less common in the United Kingdom approximately 70-90 cases per year have been reported since the introduction of the active reporting system through the British Paediatric Surveillance Unit in 1986, and this is probably still an underestimate.2 The disease manifests itself as a febrile illness associated with mucosal inflammation, lymphadenopathy, rashes, and peripheral desquamation. In approximately 20% of cases cardiovascular complications develop secondary to coronary vasculitis. The presence of coronary artery aneurysms may lead to coronary thrombosis, myocardial infarction, and in approximately 1% of cases there may be a fatal outcome. 3 The aetiology of this disease is still unknown but an infectious agent is suspected. Numerous organisms, including retroviruses, have been implicated but none confirmed. 4 The infectious aetiology theory is supported by the seasonal incidence and the epidemicq that have occurred in some countries .5 In the absence of a specific laboratory test the diagnosis at present depends on the presence of five out of six of the established clinical criteria providing other illnesses are excluded. 6 Initial screening of patients with systemic lupus erythematosus had identified a patient with high binding who was adopted as the positive standard for all experiments. Similarly a normal control sera with relatively low reactivity was selected to be a negative control for all experiments (background levels were assessed using diluent alone).
For each serum tested a binding index ratio was calculated using the following formula (OD, optical density):
(OD test sera-OD negative standard) 100 (OD positive sample-OD negative standard)
Initially 65 blood donors were screened (arithmetic mean (SD) 11 (9) ) and results were taken as abnormal if they were greater than 3SD above the mean (40%) for this group. Only one patient was positive at this level. The coefficient of variation between plates was 7-5%. ( fig 2) . (table 1) . Similarly tumour necrosis factor was shown to be effective at 90 minutes incubation.
In 15 patients tested for IgM antiendothelial cell antibodies no enhancement of the binding was seen after prestimulation of the endothelial cells with interferon gamma. There was also no enhancement found in 10 patients tested for IgG antiendothelial cell antibodies. Three of four patients showed increased binding of polyvalent antisera after stimulation of the endothelial cells with interferon gamma. Two of four patients exhibited enhanced binding of IgG antiendothelial cell antibodies after a 90 minute prestimulation of the endothelial cells with tumour necrosis factor. This was not observed in four patients tested for IgM antiendothelial cell antibodies binding after stimulation by tumour necrosis factor (table 2). 
